spend
Chronological deal log
Capital deployed by focus area
Technology modalities secured
Three underlying strategic moves
Portfolio breakdown by cluster
Engage
Ajax
Centessa
While the industry was busy debating whether GLP-1 mania had peaked, Eli Lilly went on a buying spree. Seven companies in 134 days. North of $21.2 billion in disclosed maximum potential value. And almost none of it framed, publicly, as part of a single thesis.
It should be.
Look at the dates. Ventyx Biosciences on January 7. Orna Therapeutics on February 9. Centessa Pharmaceuticals at the end of March. CrossBridge Bio, Kelonia Therapeutics, and Ajax Therapeutics in a tight April cluster. Engage Bio on May 20. Five months, seven term sheets, a tempo that even by big-pharma standards looks less like opportunism and more like a roadmap being executed.
The headline numbers tell part of the story. Centessa sits at the top at up to $7.8 billion, anchoring a real neuroscience push around OX2R agonists for sleep-wake disorders. Kelonia, at up to $7.0 billion, brings an in vivo CAR-T and gene-delivery platform plus a multiple myeloma asset, KLN-1010. Orna adds circular RNA paired with LNP delivery, aimed initially at in vivo CAR-T for autoimmune disease. Ajax contributes a first-in-class Type II JAK2 inhibitor in myelofibrosis and polycythemia vera. Ventyx layers in oral small molecules for chronic inflammation. CrossBridge brings a dual-payload ADC platform. Engage Bio rounds out its portfolio with a Tethosome non-viral DNA delivery platform.
On their own, each of these reads like a respectable tuck-in. Together, they read like a thesis.
Pattern one: platform-first, not asset-first. Orna, Kelonia, Engage, and CrossBridge are not classic “buy the Phase 3 candidate” deals. They are capability buys delivery systems, engineering layers, and therapeutic platforms that can spin out multiple programs over a decade. Lilly is paying for the factory, not just the first widget off the line.
Pattern two: diversification beyond obesity. This is the part the market keeps under-pricing. Lilly’s obesity-era cash flow is real, and management is clearly using it to broaden the next decade’s pipeline rather than double down on a single franchise. The seven deals span immunology, neuroscience, oncology, and genetic medicine. None of them is GLP-1 adjacent. That is the point.
Pattern three: building a modality stack. Look across the seven targets, and you can see the shape of it: small molecules, OX2R neuroscience, ADCs, in vivo CAR-T, and DNA/RNA delivery. That is a deliberate spread across mechanism classes, not a random scatter of bets. It is the kind of portfolio you build when you expect the next ten years of innovation to be defined by how a therapy is delivered as much as what it targets.
Cluster the deal mix, and the strategy becomes even clearer. Roughly $9.6 billion of potential consideration is pointed at genetic medicine and delivery (Orna, Kelonia, Engage). Around $2.6 billion goes to oncology (CrossBridge, Ajax). Another ~$9.0 billion sits in what can fairly be called diversification plays (Ventyx, Centessa). That is not a company nibbling at the edges. That is a company rebalancing.
There is a sober caveat worth flagging: these are maximum potential numbers, including milestone and CVR payments where disclosed. Real cash out the door will likely land below the headline. But that actually reinforces the read. Lilly is structuring deals to pay for performance, buying optionality early, and keeping its balance sheet flexible enough to keep going.
The strategic signal is the part that most coverage is missing. This is not a classic big-pharma bolt-on cycle, where a late-stage asset gets absorbed into an existing commercial machine. Lilly is buying earlier, broader, and more modular. It is acquiring the platforms that other companies will license from in five years, not just the molecules that will launch in three.
Put differently: while peers are still optimizing for the next quarterly print, Lilly seems to be quietly assembling the operating system for its post-obesity decade. Seven deals, one pattern, and a clear message to anyone paying attention. Own the platforms, not just the products.
Related News
February 2026 Deal Report: Five Signals from $53B in Activity
For media inquiries or to share perspectives on access and evidence policy, email editor@synopulse.com
